NewsHK

SRX Global draws $2.86 million in Series C preferred, settlement funded by CERO Therapeutics note assignment

8/30/2026

Structured preferred instruments remain a common bridge for small-cap issuers when cash is the scarce input, and settlement mechanics of a deal often reveal as much as the headline figure.

(NYSE American: SRXH), headquartered in North Palm Beach, Florida, disclosed on August 27, 2026 that it entered a Securities Purchase Agreement with accredited investors, selling 3,579 shares of newly designated Series C convertible preferred stock for $2,862,500.

Settlement came through investors assigning to SRX Global convertible grid promissory notes originally issued by CERO Therapeutics Holdings, Inc., with an aggregate original principal of $2,812,500.

Conversion mechanics and capital stack Each Series C share carries a stated value of $1,000.

Keep reading

Read the full story

Open on NewsHK